ASCO GU On-Site Report | Prof. Jun Guo: A Year of Strategic Momentum in Genitourinary Oncology—China’s Innovation Breaking New Ground

ASCO GU On-Site Report | Prof. Jun Guo: A Year of Strategic Momentum in Genitourinary Oncology—China’s Innovation Breaking New Ground

The 2026 Genitourinary Cancers Symposium of the American Society of Clinical Oncology (ASCO GU) was held in San Francisco, bringing together leading experts from around the world. As one of the most influential academic meetings in genitourinary oncology, the landmark studies presented each year at ASCO GU often directly shape the evolution of clinical practice globally.
JCO | Frontline BCMA CAR-T Redefines the Treatment Landscape of Multiple Myeloma: 100% MRD Negativity and 94.4% Complete Response Rate

JCO | Frontline BCMA CAR-T Redefines the Treatment Landscape of Multiple Myeloma: 100% MRD Negativity and 94.4% Complete Response Rate

In real-world clinical practice, a considerable proportion of patients with multiple myeloma (MM) are unable to tolerate autologous stem cell transplantation (ASCT) due to advanced age, comorbidities, or poor performance status, creating an urgent need for more effective therapeutic strategies. On February 27, 2026, a research paper entitled Phase II Study of BCMA Chimeric Antigen Receptor T-Cell Therapy in Patients With Newly Diagnosed Multiple Myeloma Ineligible for or Not Proceeding to Autologous Stem-Cell Transplantation (CAREMM-001) by a Chinese research team was published online in the Journal of Clinical Oncology (IF=43.4). This study provides the first prospective clinical evidence for the field, confirming that the upfront application of B-cell maturation antigen (BCMA) chimeric antigen receptor T-cell (CAR-T) therapy as first-line treatment for patients with newly diagnosed multiple myeloma (NDMM) who are ineligible for or not proceeding to transplantation—including those with high-risk disease—achieves an impressive 100% minimal residual disease (MRD) negativity rate and a 94.4% complete response rate (CRR) with a favorable safety profile. This novel therapeutic approach is expected to establish a new paradigm for MM treatment. This article summarizes the key findings of this landmark study for clinical reference.
A Comprehensive Overview of Major International Conferences in Urology and Urologic Oncology in 2026

A Comprehensive Overview of Major International Conferences in Urology and Urologic Oncology in 2026

Everything that has passed is but a prelude. Reflecting on the progress made in urologic oncology in 2025, the field witnessed the release of numerous landmark study results alongside a series of high-level international conferences. These developments have significantly expanded the boundaries of knowledge and provided invaluable platforms for researchers worldwide to exchange ideas and strengthen collaboration.
Annual Review | Prof. Xingkang Jiang and Prof. Yi Liu: Advances in Prostate Biopsy in 2025

Annual Review | Prof. Xingkang Jiang and Prof. Yi Liu: Advances in Prostate Biopsy in 2025

Prostate cancer remains the most prevalent genitourinary malignancy among men worldwide. Early and accurate diagnosis is fundamental to comprehensive disease management, long-term survival improvement, and reduction of the societal burden of disease. As the pathological gold standard for prostate cancer diagnosis, biopsy continues to serve as the central arena for technological innovation and clinical investigation in precision oncology.
Breakthrough in Advanced Renal Cancer: Prof. Hailiang Zhang and Team Propose a Precision Surgery Strategy

Breakthrough in Advanced Renal Cancer: Prof. Hailiang Zhang and Team Propose a Precision Surgery Strategy

In recent years, the combination of targeted therapy and immunotherapy has substantially improved systemic outcomes for patients with advanced clear cell renal cell carcinoma (ccRCC). However, whether these regimens can be effectively deployed in the preoperative setting as conversion therapy—enhancing surgical resectability and nephron preservation—has lacked prospective real-world validation. Furthermore, their impact on the tumor immune microenvironment remains incompletely understood.
Annual Review | Prof. Jun Guo and Prof. Juan Li: ADC–Immunotherapy Combinations Reshape First-Line Treatment for Advanced Urothelial Carcinoma

Annual Review | Prof. Jun Guo and Prof. Juan Li: ADC–Immunotherapy Combinations Reshape First-Line Treatment for Advanced Urothelial Carcinoma

The year 2025 marked a turning point in the management of advanced urothelial carcinoma (UC). Antibody–drug conjugates (ADCs) combined with immune checkpoint inhibitors (ICIs) demonstrated overwhelming advantages in the first-line setting, fundamentally challenging the long-standing dominance of platinum-based chemotherapy.
Annual Review | Prof. Pei Dong: Key Advances in Clinical Research on Renal Cell Carcinoma in China in 2025

Annual Review | Prof. Pei Dong: Key Advances in Clinical Research on Renal Cell Carcinoma in China in 2025

In 2025, China’s renal cell carcinoma (RCC) field achieved significant progress in both clinical management and translational research. Surgical innovation—particularly robotic-assisted inferior vena cava (IVC) tumor thrombus resection—has improved the feasibility and safety of complex procedures. In advanced disease, novel immunotherapy–targeted therapy combinations demonstrated promising efficacy in clear cell RCC and fumarate hydratase–deficient RCC (FH-dRCC). Meanwhile, artificial intelligence (AI)-based imaging models, metabolite-driven liquid biopsy biomarkers, multi-omics molecular subtyping, and intratumoral microbiome studies are advancing precision diagnosis, prognostic stratification, and therapeutic optimization.
On-Site at ASCO GU 2026 | Prof. Thomas Powles: HER2-Targeted Therapy Is Transforming Urothelial Carcinoma Care, with Chinese Innovation Reshaping the Global Landscape

On-Site at ASCO GU 2026 | Prof. Thomas Powles: HER2-Targeted Therapy Is Transforming Urothelial Carcinoma Care, with Chinese Innovation Reshaping the Global Landscape

The 2026 ASCO Genitourinary Cancers Symposium (ASCO GU) has once again opened as one of the most authoritative and influential global meetings in genitourinary oncology. As always, it sets the direction for advances in urothelial carcinoma, prostate cancer, and renal cell carcinoma. This year, precision-targeted therapy in urothelial carcinoma stands firmly at the center of attention.
Breaking the Adjuvant Monotherapy Standard: LITESPARK-022 Study Shows 28% Reduction in Recurrence Risk for High-Risk ccRCC

Breaking the Adjuvant Monotherapy Standard: LITESPARK-022 Study Shows 28% Reduction in Recurrence Risk for High-Risk ccRCC

At the American Society of Clinical Oncology (ASCO) Annual Meeting, Dr. Toni K. Choueiri from the Dana-Farber Cancer Institute and Harvard Medical School presented the primary results of the LITESPARK-022 study (NCT05239728). As the largest randomized, double-blind, Phase 3 trial to date in the adjuvant immunotherapy setting, LITESPARK-022 evaluated the efficacy of pembrolizumab plus belzutifan versus pembrolizumab monotherapy for patients with clear cell renal cell carcinoma (ccRCC) at increased risk of recurrence post-nephrectomy.